CHOICE for Veterans Act of 2025

The CHOICE for Veterans Act of 2025 (HR3132) was introduced in the House on May 1, 2025, and referred to the House Committee on Veterans' Affairs. On May 6, 2025, the bill was ordered to be reported out of committee by a vote of 12-11, indicating active legislative momentum. The bill is now awaiting floor action in the House. The bill's short title is the "Certified Help Options in Claims Expertise for Veterans Act of 2025" and it amends title 38, United States Code, to permit fee agreements for services rendered in the preparation, presentation, and prosecution of initial and supplemental claims for benefits under laws administered by the Secretary of Veterans Affairs. This bill does not authorize or appropriate a specific dollar amount of funding. Instead, it creates a new revenue stream for accredited agents and attorneys by allowing them to charge fees for assisting veterans with initial and supplemental claims. This structural change is a direct financial benefit to these service providers. For healthcare providers, the mechanism of impact is indirect: more efficient and professional claim submissions are expected to lead to faster processing and potentially higher reimbursement rates from the VA, as claims are less likely to be denied or delayed due to errors. This regulatory change directly expands the market for legal and claims assistance services, which in turn supports the revenue cycle management for healthcare providers. Structural winners include companies involved in healthcare services and diagnostics that serve veterans, as they stand to benefit from more efficient claims processing and potentially improved reimbursement. Companies such as HCA Healthcare ($HCA), Universal Health Services ($UHS), Labcorp Holdings ($LH), and Quest Diagnostics ($DGX) are positioned to benefit from this improved claims environment. There are no clear losers identified by this legislation, as it primarily aims to streamline and improve the claims process for veterans and those assisting them. Looking at recent market data, HCA Healthcare ($HCA) is currently at $483.92, showing a 7-day gain of +3.44% but a 30-day decline of -9.46%. Universal Health Services ($UHS) is at $181.33, with a 7-day decline of -0.42% and a 30-day decline of -7.94%. Labcorp Holdings ($LH) is at $274.46, with a 7-day gain of +4.12% and a 30-day decline of -0.53%. Quest Diagnostics ($DGX) is at $198.96, with a 7-day gain of +0.91% and a 30-day decline of -2.46%. While these companies have experienced recent fluctuations, the bill's passage would provide a long-term structural tailwind by improving the efficiency of VA claims, which could positively influence their revenue cycles. The next legislative step for HR3132 is a floor vote in the House of Representatives. Given that it has been reported out of committee, it has a clear path forward for consideration by the full House. If passed by the House, it would then move to the Senate for consideration.